Patients Can't Clear Translarna's Data Hurdles As PTC Falls Short At FDA Panel
Executive Summary
Patient testimony to the contrary, advisory committee members were not persuaded that PTC Therapeutics' ataluren, which failed its primary endpoint in two trials, is effective in treating nonsense mutation Duchenne muscular dystrophy.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
